kabutan

Perseus Proteomics Inc.(4882) Summary

4882
TSE Growth
Perseus Proteomics Inc.
237
JPY
-2
(-0.84%)
Jan 29, 1:32 pm JST
1.54
USD
Jan 28, 11:32 pm EST
Result
PTS
outside of trading hours
236.9
Jan 29, 1:29 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.59
Yield
ー%
Margin Trading Ratio
816.02
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
238 JPY 1.55 USD
Previous Close Jan 28
239 JPY 1.56 USD
High Jan 29, 9:00 am
238 JPY 1.55 USD
Low Jan 29, 9:01 am
235 JPY 1.53 USD
Volume
36,000
Trading Value
9.00M JPY 0.06M USD
VWAP
236.47 JPY 1.55 USD
Minimum Trading Value
23,700 JPY 154 USD
Market Cap
3.50B JPY 0.02B USD
Number of Trades
50
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
850
1-Year High Mar 21, 2025
12,283
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 1,409,600
Jan 16, 2026 0 1,422,400
Jan 9, 2026 0 1,476,600
Dec 26, 2025 0 1,549,500
Dec 19, 2025 0 1,727,000
Company Profile
Perseus Proteomics Inc. is a biotech venture company specializing in the development of high-performance antibody drugs and research reagents targeting cancer.
Sector
Pharmaceuticals
Perseus Proteomics Inc. is a biotech venture company that leverages its academic drug discovery network originating from the University of Tokyo to conduct research and development of antibody drugs. Utilizing proprietary antibody acquisition and engineering technologies, the company is advancing the development of therapeutic antibodies targeting cancer and hematological diseases. Its main pipeline includes PPMX-T002, a radioisotope-labeled antibody targeting cadherin 3, and PPMX-T003, an antibody targeting transferrin receptor 1. The company's revenue is derived from upfront payments from out-licensing drug candidates to domestic and international pharmaceutical companies, milestone payments based on development progress, and royalty income as a percentage of sales after market launch.